NHS losing millions in pharma cost-sharing schemes

Sharing the cost of expensive new cancer medicine with drugs companies is becoming increasingly common.

Bureaucracy may be blocking millions of pounds for which the NHS can be reimbursed, according to a survey of 31 health trusts in England.

You need to be signed in to read more


Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

  • All of HSJ.co.uk and our HSJ mobile app
  • News and insight on all areas of public funded healthcare
  • Expert commentary, insight and analysis from industry leaders
  • 9 weekly ‘Expert Briefing’ insight emails covering a variety of specialist topics

Sign into your account here